Company / Working Capital
ORAMED PHARMACEUTICALS INC. Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$114.2M
FY2025
5-year range
$88.7M / $151.4M
FY2021-FY2025
Trend
-17.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Working Capital has fluctuated over the past 10 years, ranging from $15M in FY2017 to $151M in FY2022.
Based on SEC 10-K filings.
$114M in FY2025 with a 5-year CAGR of +26.0%.
Improved from $109M to $114M over the past 2 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- -9.0%
- 5-Year CAGR
- +26.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +26.0%, indicating consistent growth.
- In FY2025, working capital decreased 17.0% year-over-year.
- Peak working capital was recorded in FY2022.
- Lowest working capital in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score 0.91 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $114.2M | -17.0% |
| FY2024 | $137.5M | +25.8% |
| FY2023 | $109.4M | -27.7% |
| FY2022 | $151.4M | +70.7% |
| FY2021 | $88.7M | +146.4% |
| FY2020 | $36.0M | +28.4% |
| FY2019 | $28.0M | +5.8% |
| FY2018 | $26.5M | +75.0% |
| FY2017 | $15.1M | -45.2% |
| FY2016 | $27.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026